UCT Private Academic Hospital
UCT Private Academic Hospital

+27 (0)21 442 1800

NEWS INDEX

UCT Private Academic Hospital

08 March 2011
Professor Jake Krige

Professor Jake Krige

Media Statement

Technology brings a “new dimension” to the treatment of liver cancer.

Cape Town, Tuesday 8 March 2011 The introduction of a new state of the art cancer treatment technology to South Africa will make more liver and lung tumours treatable, bringing hope to those suffering from these types of cancers.

Professor Jake Krige, Head of Liver Surgery at the University of Cape Town Private Academic Hospital (UCT PAH), performed South Africa’s first ever procedure with the Accu2i percutaneous microwave tissue ablation (pMTA) system at the hospital earlier this month. The groundbreaking procedure involved the removal of a primary cancer in the patient’s colon and treatment of three secondary cancer sites in the liver at the same time.

According to Microsulis Medical, which markets the Accu2i pMTA, the technology allows physicians to apply precise microwave energy to ablate liver cancers while avoiding the risks associated with longer, more invasive surgical interventions. A 1.8 mm diameter needle, which can be inserted via a puncture in the skin, allows physicians to ablate liver cancers up to five centimetres in diameter in a matter of minutes.

Liver cancer treatment usually involves one of the following treatments: the surgical removal of tumours, chemotherapy, or radiofrequency ablation (RFA). Sometimes a combination of these treatments is used.

Prof Krige said that the Accu2i pMTA performed beyond his expectations during the procedure and was easier to handle than the microwave tissue ablation technology that was available previously. The new system ablated tumours more quickly and efficiently than traditional RFA systems, achieving an ablation rate three times faster than RFA. “The technology provides a completely new dimension to the treatment of patients with complex liver tumours,” he pointed out.

The Accu2i pMTA allows larger ablations to be performed which means that this type of therapy will be an option for more liver cancer patients. The technology is also groundbreaking in that it allows patients with more severe disease to be treated, according to Microsulis Medical.

During the Cape Town procedure, which was performed on retired headmaster Mr Rudolf Visser, Prof Krige used the Accu2i pMTA to ablate two 1.5cm and one 2.5cm liver tumours.

Rudolf Visser first had symptoms of his cancer in April 2010, when he suffered severe stomach cramps. A colonoscopy detected the colon cancer and Mr Visser was treated with chemotherapy between May and November 2010, which succeeded in shrinking the liver tumours. He was then referred to Prof Krige at the UCT PAH for advanced tertiary specialist surgical treatment.

In a four-hour operation on 9 February, Prof Krige removed half of Mr Visser’s large intestine including the primary colon cancer and the lymph nodes. Prof Krige then used intra-operative ultrasound to guide and monitor the microwave ablation of the three secondary cancers in the liver.

According to Rudolf Visser’s wife Poppie, the procedures were a great success and Rudolf is doing very well. “I thank God who I believe guided Professor Krige’s hands during the operation and made Rudolf’s recovery possible,” she said.

UCT Private Academic Hospital (UCT PAH) Manager Christo Bekker suggested that Prof Krige had broken “new ground in cancer treatment in South Africa” and the hospital was immensely proud of his achievement. “The new technique would allow some liver cancer patients to be treated who were previously thought to be untreatable,” he concluded. “I think it is no exaggeration to say that this procedure is a great step forward in South African cancer medicine”. 

Ends

Issued by: Martina Nicholson Associates (MNA) on behalf of UCT Private Academic Hospital
Contact: Martina Nicholson, Graeme Swinney or Clementine Eccles
Telephone: (011) 469 3016
Email: martina@mnapr.co.za or graeme@mnapr.co.za


Mediaverklaring

Universiteit van Kaapstad se Private Akademiese Hospitaal

Behandeling van lewerkanker betree 'n nuwe era danksy nuwe tegnologie

Kaapstad, Dinsdag 8 Maart 2011 Die bekendstelling van die nuutste tegnologie op die gebied van kankerbehandeling in Suid-Afrika sal beteken dat meer lewer- en longgewasse nou behandel kan word, wat nuwe hoop bring vir pasiënte wat aan hierdie tipe  kanker ly.

Prof Jake Krige, hoof van lewerchirurgie aan die Universiteit van Kaapstad se Private Akademiese Hospitaal, het vroeër vandeesmaand Suid-Afrika se eerste prosedure met die Accu2i pMTA-stelsel (mikrogolftegnologie vir die ablasie of verwydering van weefsel deur die vel) by die hospitaal uitgevoer. Hierdie vernuwende prosedure het die gelyktydige verwydering van 'n primêre kanker in die pasiënt se kolon asook die behandeling van drie sekondêre kankergewasse in die lewer behels.

Volgens Microsulis Medical, die maatskappy wat die Accu2i pMTA bemark, maak die tegnologie dit vir medici moontlik om presiese hoeveelhede mikrogolfenergie te gebruik om lewerkankergewasse te verwyder terwyl die risiko's gepaardgaande met langer, meer indringende chirurgiese ingrype vermy word. 'n Naald met 'n deursnee van 1.8 mm wat deur die vel ingesteek word, maak dit vir dokters moontlik om lewerkankergewasse van tot vyf sentimeter in slegs 'n paar minute te verwyder.

Lewerkankerbehandeling behels gewoonlik een van die volgende behandelings:  die chirurgiese verwydering van gewasse; chemoterapie; of radiofrekwensie-ablasie (RFA). Soms word 'n kombinasie van hierdie drie metodes gebruik.

Volgens prof Krige het die Accu2i pMTA verwagtinge tydens die prosedure oortref, en dat dit makliker was om te gebruik as die mikrogolf-ablasietegnologie wat voorheen beskikbaar was. Die nuwe stelsel het gewasse vinniger en meer doeltreffend verwyder as tradisionele RFA-stelsels, en kon 'n ablasie drie keer vinniger as RFA uitvoer. “Die tegnologie bied 'n heeltemal nuwe dimensie vir die behandeling van pasiënte met komplekse lewergewasse,” sê hy.

Die Accu2i pMTA maak dit moontlik om groter ablasies uit te voer, en beteken dat hierdie tipe terapie nou 'n opsie vir meer lewerkankerpasiënte word. Die terapie is ook vernuwend in dié sin dat pasiënte met 'n meer ernstige vorm van die siekte ook behandel kan word, volgens Microsulis Medical.

Tydens die prosedure in Kaapstad, wat op afgetrede skoolhoof mnr Rudolf Visser uitgevoer is, het prof Krige die Accu2i pMTA-tegnologie gebruik om twee lewergewasse van 1.5 cm en een lewergewas van 2.5 cm te verwyder.

Die eerste simptome wat Visser ondervind het, was in April 2010 toe hy ernstige maagkrampe gehad het. 'n Kolonoskopie het die kolonkanker opgespoor en Visser is tussen Mei en November 2010 met chemoterapie behandel, wat die lewergewasse laat krimp het. Hy is in daardie stadium na prof Krige by UK se Private Akademiese Hospitaal vir gevorderde tersiêre chirurgiese behandeling verwys.

In 'n vieruurlange operasie op 9 Februarie het prof Krige die helfte van Visser se dikderm, met inbegrip van die primêre kolonkanker en die limfnodusse, verwyder. Prof Krige het daarna intra-operatiewe ultraklanktegnologie gebruik om die mikrogolfablasie van drie sekondêre kankers in die lewer te lei en te monitor.

Volgens mev. Poppie Visser sterk haar man goed aan en was die prosedures 'n groot sukses. “Ek dank die Here wat dat ek glo prof Krige se hande tydens die operasie vasgehou het en Rudolf se herstel moontlik gemaak het,” sê sy.

Volgens Christo Bekker, bestuurder van UK se Private Akademiese Hospitaal,  het prof Krige “'n nuwe era in kankerbehandeling in Suid-Afrika ingelui” en voeg by dat die hospitaal geweldig trots op sy prestasie is. “Met die nuwe tegniek kan sommige kankerpasiënte nou behandel word wat voorheen as onbehandelbaar beskou is,” sê hy. “Ek dink dit is geensins 'n oordrywing om te sê dat hierdie prosedure 'n groot stap vorentoe in Suid-Afrikaanse kankerbehandeling is nie.”

Einde

Uitgereik deur: Martina Nicholson Associates (MNA) namens Universiteit Kaapstad se Private Akademiese Hospitaal 

Kontak: Martina Nicholson, Graeme Swinney of Clementine Eccles

Telefoon: (011) 469 3016

Epos: martina@mnapr.co.za of Graeme@mnapr.co.za